Colin Terry

Colin is a Partner and leader in our UK / Swiss Life Science practice. He has been with Deloitte since 2011 working in the US firm until 2014 when he moved to the UK. ​

Colin’s client advisory work in the Life Sciences sector ranges from strategy into operations focused on the R&D function including operating model development and implementation as well as post-merger integration (PMI). These engagements have been serving client Boards and their senior leadership teams in R&D, Commercial and Private Equity. ​

Colin is the co-author of our annual R&D productivity and IRR analysis study which reviews productivity of the worlds largest pharmaceutical businesses. ​

His recent engagements include developing a vision of the future R&D model including internal and external attributes; creating a digital R&D strategy and business cases of new technologies and pilot programs; design and implementation of a world first GXP validated Robotic Process Automation; and design of a new Pharma vaccine R&D model post integration​

Colin has a B.Sc (Hons). in Microbiology from the University of London, Queen Mary & Westfield and a Marketing Diploma from the Chartered Institute of Marketing.